Drug intelligence / Profile preview

GLCP-086-1

Development stage: Preclinical
Lead developer: Glicothera
Modality: Small Molecules
Administration: Oral

Overview

GLCP-086-1 is a small molecule inhibitor of the c-Jun N-terminal kinase (JNK) pathway, currently in preclinical development by Galenicap. It is being investigated as a neuroprotective agent for the treatment of ischemic stroke, specifically to be administered in conjunction with mechanical thrombectomy. The JNK pathway is a key mediator of neuronal death (apoptosis) following ischemic insult and reperfusion. By inhibiting this pathway, GLCP-086-1 aims to mitigate the secondary brain injury that occurs after the restoration of blood flow, thereby preserving neurological function and improving patient recovery.

Other names: GLCP-086-1GLCP086-1GLCP 086-1

Targets

JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on GLCP-086-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLCP-086-1.

Explore the full profile